A South Korea based leading global pharmaceutical company approached Freyr to assess the suitability of study data of its European Union submission and applicable Good Clinical Practices (GCP). Since the study was already conducted, Freyr had to carry out the audit in retrospection. The major challenge faced by Freyr was the strict timeline of two weeks and to go through the bioanalytical data of the client which was not at all audit ready.

Download the case study to know how Freyr managed to complete the project with quick TAT and saved up to 40% cost.